9: Evaluation of Aerosolized Epoprostenol in COVID-19 ARDS Patients

摘要: INTRODUCTION: ARDS contributes to high mortality and morbidity observed with coronavirus disease 2019 (COVID-19) Epoprostenol has antithrombotic, antiproliferative, vasodilatory properties improves respiratory parameters in The role of aerosolized epoprostenol (aEPO) COVID-19 not been evaluated We hypothesized that aEPO may improve oxygenation intubated patients METHODS: performed a single-center, retrospective, propensity-score matched cohort study A medical chart review was conducted for adult admitted between March 1, 2020 May Patients receiving (0 05 mcg/kg/minute) versus were Rothman index baseline PaO2:FiO2 (PF) ratios, effect on PF ratio, gradient arterial end-tidal CO2, dead space (primary endpoints) Secondary endpoints included in-hospital mortality, mechanical ventilation-free days, ICU hospital length stay Safety incidence hypotension, significant bleeding, thrombocytopenia, rebound hypoxemia RESULTS: Nineteen treated compared 19 propensity-matched controls Baseline characteristics well Management similar groups mean ± SD duration treatment 5 2 8 days There no differences ratios non-aEPO at 3 hours (125 56 vs 115 40 mmHg), 6 (124 41 147 73 12 (112 39 163 62 24 (114 33 176 64 48 (150 54 212 84 although there trend toward higher the control group CO2 cohorts significantly more deaths by day 10 (21% 0, p<0 05), though difference 28-day (41% 48%, p=0 35) other secondary safety end points CONCLUSIONS: In this small case-control study, did demonstrate better efficacy or Large randomized trials are needed confirm early survival benefit noted